This paper studies the long-term effectiveness and safety of dupilumab (a medication that blocks certain inflammatory signals) when used together with topical corticosteroids in treating moderate-to-severe atopic dermatitis. The study lasted for one year and compared dupilumab plus topical steroids against placebo plus topical steroids.
-
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin-Weller, Melinda Gooderham, Jennifer C Cather, Jamie Weisman, David Pariser, Eric L Simpson, Kim A Papp, H Chih-Ho Hong, Diana Rubel, Peter Foley, Errol Prens, Christopher E M Griffiths, Takafumi Etoh, Pedro Herranz Pinto, Ramon M Pujol, Jacek C Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M H Graham, Gianluca Pirozzi, Neil Stahl, George D Yancopoulos, Brad Shumel
DOI: 10.1016/S0140-6736(17)31191-1
Controlled Clinical Trial
•
740 participants
•
2017
•
345 citations
Key insights related to Dupixent from this study:
-
What is this paper about?
-
How did the authors study this?
This was a large clinical trial conducted at 161 medical centers across 14 countries. Patients were randomly assigned to receive either dupilumab weekly, dupilumab every two weeks, or placebo - all groups also used topical corticosteroids. The researchers measured improvement in skin appearance and severity of eczema at 16 weeks and 52 weeks.
-
What populations did the authors study?
The study included adults with moderate-to-severe atopic dermatitis who hadn't responded well enough to topical corticosteroids alone. A total of 740 patients participated in the study from different regions including Europe, Asia-Pacific, and North America.
-
What did the authors find?
After 16 weeks, 39% of patients on dupilumab (both dosing schedules) showed clear or almost clear skin, compared to only 12% in the placebo group. Even more patients (64-69% on dupilumab versus 23% on placebo) showed significant improvement in their eczema severity. These improvements lasted through the full year of treatment. Side effects were similar between groups, though injection site reactions and eye inflammation were more common with dupilumab.
-
What conclusions can we draw?
The authors concluded that adding dupilumab to topical corticosteroid treatment for one year effectively improved atopic dermatitis symptoms and was safe to use. This treatment combination provided better results than using topical corticosteroids alone.
Did this article interest you?
As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.
Ready for better skin health?
At Lemma Health, we provide evidence-based skin care. Access dermatologists in all 50 states. Appointments available within 3 days. Receive your medications delivered. Get ongoing 24/7/365 support. Coordinate your care across specialties.